Atropos Health, a company translating real-world clinical data into real-world evidence (RWE) for decision making, is partnering with xCures, an AI-powered healthcare data retrieval company, to harness RWE-based insights to support patient care.

The aim of the partnership is to leverage AI, the Atropos Evidence Network and the xCures Platform in order to "develop and deploy validated prognostic and decision support tools to healthcare providers across the healthcare ecosystem."

Additionally, the partners plan to develop tools that deliver detectable, source-verified insights from raw clinical notes, analytics and imaging data to be used directly into clinical workflows. 

The tools will allow providers to make faster, data-informed decisions tailored to particular patients, with the aim of closing the gap between evidence generation and actionable outcomes.

According to xCures, its platform functions as an AI-powered intelligent layer over Health Information Exchanges (HIEs) and Qualified Health Information Networks (QHINs), aligning with the standards outlined by the U.S. Department of Health and  Human Services under The Trusted Exchange Framework and Common Agreement (TEFCA).

The xCures platform is designed to support interoperability and data exchange as well as ensure compliance while enhancing the utility of healthcare data for personalized treatment planning and clinical decision support. 

"Removing data silos and doing it in a manner that meets the highest standards of accuracy and compliance aligns with our mission," Brigham Hyde, CEO and cofounder at Atropos Health, said in a statement.

"The state of healthcare data, with the use of AI, can rapidly advance precision medicine. Together with xCures, by utilizing the portfolio of Atropos Health services such as GENEVA OS, Green Button, Atropos Evidence Network and Alexandria, shared decision making in clinical settings based on RWE is becoming a reality and an important time-saving tool for physicians.

THE LARGER TREND

Earlier this month, Atropos Health partnered with Merck to generate RWE, replicate studies, and produce rapid insights and analytics on real-world data. Via the partnership, Atropos Health will enable rapid cohort creation, advanced analytics and publication-grade studies in less than 48 hours.  

Atropos Health secured $33 million in Series B funding last year. Valtruis led the investment round, which included new investors McKesson Ventures, Merck GHI Fund and Cencora Ventures. 

Existing investors Emerson Collective, Breyer Capital and Presidio Ventures also participated in the round. Mike Spadafore, managing director of Valtruis, was named to the company's board of directors.

In August, Brigham Hyde, CEO of Atropos Health, joined MobiHealthNews' Digital Health Investment Series when he discussed the crucial internal and external factors companies must consider before and while approaching investors. He also shared his views on the longevity of AI use in healthcare.

"We made a decision, and we were working on some things already, but we made the decision to double down on generative AI ... and I think that's a good decision. It helped us in the fundraising process," Hyde told MobiHealthNews. 

"Now, we had to put that through the lens of whether it is still core to our principles, which are greater user experience, driving value for users and customers, and creating value in the system. That application passes that mark for us."